Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANHYDRON vs LINACLOTIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Agonist of guanylate cyclase-C (GC-C) receptor on luminal surface of intestinal epithelial cells, increasing cyclic guanosine monophosphate (c GMP) levels, which activates CFTR ion channel, increasing chloride and water secretion into intestinal lumen, accelerating colonic transit and reducing visceral pain.
Edema associated with congestive heart failure, cirrhosis of the liver, and renal disease,Hypertension (off-label use)
Irritable bowel syndrome with constipation (IBS-C),Chronic idiopathic constipation (CIC)
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
145 mcg orally once daily, at least 30 minutes before the first meal of the day.
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Approximately 9–10 hours (terminal half-life in plasma), supporting once-daily dosing.
Partially metabolized by the liver; primarily excreted unchanged in urine.
Minimally metabolized; primarily degraded by intestinal peptidases. Not a substrate for CYP450 enzymes.
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Primarily fecal as intact peptide (95%); renal excretion of absorbed drug is minimal (<5%).
95% bound, primarily to albumin.
Approximately 94% bound to plasma proteins (primarily albumin).
0.2-0.3 L/kg, reflecting distribution primarily in extracellular fluid.
~5.2 L/kg (large Vd indicating extensive tissue distribution).
Oral: ~65% (range 50-80%) due to first-pass metabolism.
Oral: ~0.1% (extremely low due to extensive degradation in GI tract and first-pass metabolism).
GFR 10-50 m L/min: 50 mg every 12 hours. GFR <10 m L/min: 50 mg every 24 hours or not recommended.
No dose adjustment required for any degree of renal impairment, including end-stage renal disease on dialysis.
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe hepatic impairment (Child-Pugh C): avoid use.
No dose adjustment required for mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, or C).
1-2 mg/kg/dose once daily; maximum 100 mg/day.
Not approved for use in pediatric patients; safety and efficacy not established.
Start at 12.5-25 mg once daily; titrate slowly due to risk of hypotension and electrolyte imbalance.
No specific dose adjustment; caution advised due to potential increased sensitivity or gastrointestinal effects, but no pharmacokinetic differences observed in elderly vs younger adults.
No FDA black box warning.
No boxed warning.
Electrolyte imbalance (hypokalemia, hyponatremia, hypochloremia),Dehydration and hypotension,Ototoxicity (especially with rapid IV administration or renal impairment),Hyperuricemia and gout,Sulfonamide cross-sensitivity in sulfa-allergic patients
Not recommended in pediatric patients; avoid use in patients with known or suspected mechanical gastrointestinal obstruction.,May cause diarrhea, which can be severe; instruct patients to discontinue if severe diarrhea occurs.,Use caution in patients with inflammatory bowel disease (Crohn's, ulcerative colitis) or a history of colonic obstruction.
Anuria,Severe renal failure,Hepatic coma or pre-coma,Severe electrolyte depletion,Hypersensitivity to sulfonamides
Known or suspected mechanical gastrointestinal obstruction.,History of a serious hypersensitivity reaction to linaclotide or any component of the formulation.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) as hyperkalemia may occur. Limit salt substitutes containing potassium. Grapefruit juice may increase drug absorption; avoid concurrent use. Alcohol may enhance orthostatic hypotension.
Food reduces the efficacy of linaclotide; administer at least 30 minutes before a meal. Avoid taking with high-fat meals as they may delay gastric emptying and reduce drug effect. No specific dietary restrictions but maintaining adequate hydration is recommended due to possible diarrhea.
Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been associated with an increased risk of congenital anomalies in some studies, including cleft lip/palate and cardiac defects. Second and third trimesters: can cause fetal or neonatal jaundice, thrombocytopenia, electrolyte disturbances, and possibly intrauterine growth restriction. Crosses the placenta. Use only if clearly needed for maternal conditions like hypertension or edema.
Linaclotide is not systemically absorbed after oral administration; animal studies at high oral doses showed no teratogenicity. No human data available; risk to fetus is likely low due to negligible systemic exposure.
Cyclothiazide is excreted into human breast milk. The milk-to-plasma ratio is not well defined for cyclothiazide but for thiazides generally is around 0.5-1.0. May suppress lactation. Potential for infant adverse effects (e.g., electrolyte disturbances, thrombocytopenia). Use caution in breastfeeding; alternatives are preferred.
Linaclotide is minimally absorbed systemically; its active metabolite is not measurable in plasma. No data on presence in human milk. M/P ratio unknown; likely low risk due to poor oral bioavailability and large molecular size.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal blood flow, and GFR) may reduce effectiveness of thiazides. No specific dosing adjustment guidelines for cyclothiazide; however, if used, start at lowest effective dose and titrate based on response. Typical adult dose: 2 mg once daily; may adjust to 1-4 mg. Monitor for hypotension and electrolyte imbalances. Avoid in preeclampsia due to decreased placental perfusion.
No dose adjustment needed; pharmacokinetic changes in pregnancy do not affect systemic exposure due to negligible absorption.
ANHYDRON (cyclothiazide) is a thiazide-like diuretic used for hypertension and edema. Monitor serum potassium and glucose levels; hypokalemia and hyperglycemia are common. Use with caution in renal impairment (Cr Cl <30 m L/min). Avoid in patients with anuria or sulfonamide allergy.
Linaclotide is a guanylate cyclase-C agonist approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Onset of action can occur within 24 hours but maximal effect may take 1-2 weeks. Contraindicated in pediatric patients under 6 years due to risk of severe diarrhea. Avoid use in patients with mechanical gastrointestinal obstruction. Monitor for diarrhea, which may require dose reduction or discontinuation. Capsules should be swallowed whole; do not crush or chew. For patients with difficulty swallowing, capsules may be opened and sprinkled on applesauce or mixed in water for immediate consumption. Renal or hepatic impairment does not require dose adjustment. Linaclotide is not systemically absorbed (active locally).
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,May cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,Do not stop abruptly without consulting your doctor; gradual dose reduction may be needed.
Take linaclotide on an empty stomach, at least 30 minutes before the first meal of the day.,Swallow capsules whole; do not crush, chew, or break. If needed, open capsule and mix contents with applesauce or water and take immediately.,Do not take within 1 hour of eating or if you have a bowel obstruction.,Common side effects include diarrhea, which may be severe. Stop the medication and contact your doctor if you experience persistent or severe diarrhea.,Do not use in children under 6 years old.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANHYDRON vs LINACLOTIDE, answered by our medical review team.
ANHYDRON is a Thiazide Diuretic that works by Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. LINACLOTIDE is a Guanylate Cyclase-C Agonist that works by Agonist of guanylate cyclase-C (GC-C) receptor on luminal surface of intestinal epithelial cells, increasing cyclic guanosine monophosphate (c GMP) levels, which activates CFTR ion channel, increasing chloride and water secretion into intestinal lumen, accelerating colonic transit and reducing visceral pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANHYDRON and LINACLOTIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANHYDRON is: Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.. The standard adult dose of LINACLOTIDE is: 145 mcg orally once daily, at least 30 minutes before the first meal of the day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANHYDRON and LINACLOTIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANHYDRON is classified as Category C. Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been asso. LINACLOTIDE is classified as Category C. Linaclotide is not systemically absorbed after oral administration; animal studies at high oral doses showed no teratogenicity. No human data available; risk to fetus is likely low. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.